Literature DB >> 15748945

The immunostimulatory activity of CpG oligonucleotides on microglial N9 cells is affected by a polyguanosine motif.

Zhiren Zhang1, Ketai Guo, Hermann J Schluesener.   

Abstract

Oligonucleotides (ODN) with hexameric motifs containing central unmethylated CpG dinucleotides are immunostimulatory. Also ODN with continuous guanosines (polyG motif) show a wide range of immunological activity. Depending on the position, the chemical property of the ODN backbone and the cell type, polyG motifs have either an enhancing or a suppressing effect on the immunostimulatory activity of the CpG-ODN. Microglial cells are central components of the innate immune system of the brain and are activated by CpG-ODN in vitro and in vivo. Here we present the analysis of the immunomodulatory effects of CpG-ODN carrying a polyG motif on the microglial cell line N9. Our data show that N9 cells express Toll-like receptor 9 (TLR9) and are activated by CpG-ODN, which leads to expression of interleukin-12p40 (IL12p40), tumor necrosis factor-alpha (TNF-alpha) and inducible nitric oxide synthase (iNOS). A 3'-end polyG motif inhibits phosphothioate (PS) CpG-ODN immunostimulatory activity but enhances the immunostimulatory activity of phosphodiester (PE) CpG-ODN. Correspondingly, a 3'-end polyG motif improves the cellular uptake of PE CpG-ODN but does not change their cellular distribution pattern. Furthermore, PE CpG-ODN with a 3'-end polyG motif interact with a much higher number of cellular proteins than PE CpG-ODN. These data indicate that the 3'-end polyG motif could enhance the immunostimulatory activity of PE CpG-ODN in microglial N9 cells through increasing interaction with cellular proteins. Therefore PE CpG-ODN containing a 3'-end polyG motif resulting in increased immunostimulatory activity might be promising alternate analogues for studies in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15748945     DOI: 10.1016/j.jneuroim.2004.12.009

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  9 in total

Review 1.  Toll-like receptors in defense and damage of the central nervous system.

Authors:  Rajagopal N Aravalli; Phillip K Peterson; James R Lokensgard
Journal:  J Neuroimmune Pharmacol       Date:  2007-04-03       Impact factor: 4.147

Review 2.  Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.

Authors:  Paula J Bates; Damian A Laber; Donald M Miller; Shelia D Thomas; John O Trent
Journal:  Exp Mol Pathol       Date:  2009-01-20       Impact factor: 3.362

3.  Inhibition of TLR ligand- and interferon gamma-induced murine microglial activation by Panax notoginseng.

Authors:  Celine A Beamer; David M Shepherd
Journal:  J Neuroimmune Pharmacol       Date:  2011-12-21       Impact factor: 4.147

Review 4.  Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential.

Authors:  Mark L Hanke; Tammy Kielian
Journal:  Clin Sci (Lond)       Date:  2011-11       Impact factor: 6.124

Review 5.  Toll-like receptors in central nervous system glial inflammation and homeostasis.

Authors:  Tammy Kielian
Journal:  J Neurosci Res       Date:  2006-04       Impact factor: 4.164

Review 6.  Overview of toll-like receptors in the CNS.

Authors:  Tammy Kielian
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

Review 7.  Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology.

Authors:  Fernando Pena-Ortega
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

8.  CpG Oligonucleotides Protect Mice From Alphavirus Encephalitis: Role of NK Cells, Interferons, and TNF.

Authors:  Mohanraj Manangeeswaran; Aaron P Lewkowicz; Tomer Israely; Derek D C Ireland; Daniela Verthelyi
Journal:  Front Immunol       Date:  2020-02-18       Impact factor: 7.561

Review 9.  Activation of Innate Immunity by Therapeutic Nucleic Acids.

Authors:  Ali Bishani; Elena L Chernolovskaya
Journal:  Int J Mol Sci       Date:  2021-12-12       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.